InMed Pharmaceuticals Inc. (NASDAQ: INM) Is ‘One to Watch’
InMed has a world class leadership team with a successful track record of drug development and commercialization The company recently announced closing of a $12 million private placement InMed has a solid and expanding intellectual property portfolio with multiple patents filed The company recently signed an LOI to acquire rare cannabinoids manufacturer BayMedica InMed retains all commercial rights to its IntegraSyn manufacturing system InMed has filed clinical trial applications in several countries as part of a Phase 2 clinical trial of INM-755 (cannabinol) cream in epidermolysis bullosa The consumer market for cannabinoid-based pharmaceuticals in the United States is forecast to…
